CD21-/low B cells: A Snapshot of a Unique B Cell Subset in Health and Disease

Scandinavian Journal of Immunology

Volumn 82, Issue 3, 2015, Pages 254-261

  Thorarinsdottir, K ^a   Camponeschi, A ^a   Gjertsson, I ^a   Martensson I L ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3D RECEPTOR; AUTOANTIBODY; BELIMUMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; RITUXIMAB;

ANTIGEN EXPRESSION; B LYMPHOCYTE; COMMON VARIABLE IMMUNODEFICIENCY; CRYOGLOBULINEMIA; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSTIMULATION; LYMPHOCYTE SUBPOPULATION; MALARIA; MEMORY CELL; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; AUTOIMMUNE DISEASES; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOCYTE DEPLETION; VIROLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOANTIBODIES; AUTOIMMUNE DISEASES; B-LYMPHOCYTE SUBSETS; HIV INFECTIONS; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE DEPLETION; RECEPTORS, COMPLEMENT 3D;

EID: 84939235527     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12339     Document Type: Review

References (80)

1. Nemazee D. Receptor editing in lymphocyte development and central tolerance. Nat Rev Immunol 2006;6:728-40.
2. Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 2005;435:590-7.
3. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science 2003;301:1374-7.
4. Meffre E, Wardemann H. B-cell tolerance checkpoints in health and autoimmunity. Curr Opin Immunol 2008;20:632-8.
5. Yurasov S, Nussenzweig MC. Regulation of autoreactive antibodies. Curr Opin Rheumatol 2007;19:421-6.
6. Keenan RA, De Riva A, Corleis B et al. Censoring of autoreactive B cell development by the pre-B cell receptor. Science 2008;321:696-9.
7. Grimsholm O, Ren W, Bernardi AI et al. Absence of surrogate light chain results in spontaneous autoreactive germinal centres expanding VH81X-expressing B cells. Nat Commun 2015;6:7077.
8. Rantapaa-Dahlqvist S, de Jong BA, Berglin E et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
9. Brink M, Hansson M, Mathsson L et al. Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis Rheum 2013;65:899-910.
10. Klein U, Kuppers R, Rajewsky K. Evidence for a large compartment of IgM-expressing memory B cells in humans. Blood 1997;89:1288-98.
11. Capolunghi F, Rosado MM, Sinibaldi M, Aranburu A, Carsetti R. Why do we need IgM memory B cells? Immunol Lett 2013;152:114-20.
12. Sanz I, Wei C, Lee FE, Anolik J. Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol 2008;20:67-82.
13. Bergmann B, Grimsholm O, Thorarinsdottir K et al. Memory B cells in mouse models. Scand J Immunol 2013;78:149-56.
14. Tarlinton D, Good-Jacobson K. Diversity among memory B cells: origin, consequences, and utility. Science 2013;341:1205-11.
15. Weill JC, Le Gallou S, Hao Y, Reynaud CA. Multiple players in mouse B cell memory. Curr Opin Immunol 2013;25:334-8.
16. Good-Jacobson KL, Shlomchik MJ. Plasticity and heterogeneity in the generation of memory B cells and long-lived plasma cells: the influence of germinal center interactions and dynamics. J Immunol 2010;185:3117-25.
17. Giesecke C, Frolich D, Reiter K et al. Tissue distribution and dependence of responsiveness of human antigen-specific memory B cells. J Immunol 2014;192:3091-100.
18. Toyama H, Okada S, Hatano M et al. Memory B cells without somatic hypermutation are generated from Bcl6-deficient B cells. Immunity 2002;17:329-39.
19. Weill JC, Weller S, Reynaud CA. Human marginal zone B cells. Annu Rev Immunol 2009;27:267-85.
20. Weis JJ, Tedder TF, Fearon DT. Identification of a 145, 000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes. Proc Natl Acad Sci USA 1984;81:881-5.
21. Ross GD, Lambris JD. Identification of a C3bi-specific membrane complement receptor that is expressed on lymphocytes, monocytes, neutrophils, and erythrocytes. J Exp Med 1982;155:96-110.
22. Ahearn JM, Fearon DT. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv Immunol 1989;46:183-219.
23. Nadler LM, Stashenko P, Hardy R, van Agthoven A, Terhorst C, Schlossman SF. Characterization of a human B cell-specific antigen (B2) distinct from B1. J Immunol 1981;126:1941-7.
24. Iida K, Nadler L, Nussenzweig V. Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody. J Exp Med 1983;158:1021-33.
25. Fischer E, Delibrias C, Kazatchkine MD. Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes. J Immunol 1991;146:865-9.
26. Reynes M, Aubert JP, Cohen JH et al. Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens. J Immunol 1985;135:2687-94.
27. Cherukuri A, Cheng PC, Pierce SK. The role of the CD19/CD21 complex in B cell processing and presentation of complement-tagged antigens. J Immunol 2001;167:163-72.
28. Cambier JC, Pleiman CM, Clark MR. Signal transduction by the B cell antigen receptor and its coreceptors. Annu Rev Immunol 1994;12:457-86.
29. Fingeroth JD, Weis JJ, Tedder TF, Strominger JL, Biro PA, Fearon DT. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci USA 1984;81:4510-4.
30. Aubry JP, Pochon S, Gauchat JF et al. CD23 interacts with a new functional extracytoplasmic domain involving N-linked oligosaccharides on CD21. J Immunol 1994;152:5806-13.
31. Asokan R, Hua J, Young KA et al. Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-alpha: a potential role in systemic lupus erythematosus. J Immunol 2006;177:383-94.
32. Fearon DT. The CD19-CR2-TAPA-1 complex, CD45 and signaling by the antigen receptor of B lymphocytes. Curr Opin Immunol 1993;5:341-8.
33. Fearon DT, Carter RH. The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annu Rev Immunol 1995;13:127-49.
34. Carter RH, Tuveson DA, Park DJ, Rhee SG, Fearon DT. The CD19 complex of B lymphocytes. Activation of phospholipase C by a protein tyrosine kinase-dependent pathway that can be enhanced by the membrane IgM complex. J Immunol 1991;147:3663-71.
35. Matsumoto AK, Kopicky-Burd J, Carter RH, Tuveson DA, Tedder TF, Fearon DT. Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19. J Exp Med 1991;173:55-64.
36. Masilamani M, Apell HJ, Illges H. Purification and characterization of soluble CD21 from human plasma by affinity chromatography and density gradient centrifugation. J Immunol Methods 2002;270:11-8.
37. Aichem A, Masilamani M, Illges H. Redox regulation of CD21 shedding involves signaling via PKC and indicates the formation of a juxtamembrane stalk. J Cell Sci 2006;119:2892-902.
38. Ling NR, Hardie DL, Johnson GD, MacLennan IC. Origin and properties of soluble CD21 (CR2) in human blood. Clin Exp Immunol 1998;113:360-6.
39. Ling N, Hansel T, Richardson P, Brown B. Cellular origins of serum complement receptor type 2 in normal individuals and in hypogammaglobulinaemia. Clin Exp Immunol 1991;84:16-22.
40. Lowe J, Brown B, Hardie D, Richardson P, Ling N. Soluble forms of CD21 and CD23 antigens in the serum in B cell chronic lymphocytic leukaemia. Immunol Lett 1989;20:103-9.
41. Masilamani M, Kassahn D, Mikkat S, Glocker MO, Illges H. B cell activation leads to shedding of complement receptor type II (CR2/CD21). Eur J Immunol 2003;33:2391-7.
42. Huemer HP, Larcher C, Prodinger WM, Petzer AL, Mitterer M, Falser N. Determination of soluble CD21 as a parameter of B cell activation. Clin Exp Immunol 1993;93:195-9.
43. Wehr C, Eibel H, Masilamani M et al. A new CD21low B cell population in the peripheral blood of patients with SLE. Clin Immunol 2004;113:161-71.
44. Masilamani M, von Kempis J, Illges H. Decreased levels of serum soluble complement receptor-II (CR2/CD21) in patients with rheumatoid arthritis. Rheumatology 2004;43:186-90.
45. Palanichamy A, Barnard J, Zheng B et al. Novel human transitional B cell populations revealed by B cell depletion therapy. J Immunol 2009;182:5982-93.
46. Bemark M, Holmqvist J, Abrahamsson J, Mellgren K. Translational Mini-Review Series on B cell subsets in disease. Reconstitution after haematopoietic stem cell transplantation - revelation of B cell developmental pathways and lineage phenotypes. Clin Exp Immunol 2012;167:15-25.
47. Isaak A, Prechl J, Gergely J, Erdei A. The role of CR2 in autoimmunity. Autoimmunity 2006;39:357-66.
48. Ehrhardt GR, Hsu JT, Gartland L et al. Expression of the immunoregulatory molecule FcRH4 defines a distinctive tissue-based population of memory B cells. J Exp Med 2005;202:783-91.
49. Ehrhardt GR, Hijikata A, Kitamura H, Ohara O, Wang JY, Cooper MD. Discriminating gene expression profiles of memory B cell subpopulations. J Exp Med 2008;205:1807-17.
50. Isnardi I, Ng YS, Menard L et al. Complement receptor 2/CD21- human naive B cells contain mostly autoreactive unresponsive clones. Blood 2010;115:5026-36.
51. Moir S, Malaspina A, Ogwaro KM et al. HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci USA 2001;98:10362-7.
52. Sciaranghella G, Tong N, Mahan AE, Suscovich TJ, Alter G. Decoupling activation and exhaustion of B cells in spontaneous controllers of HIV infection. AIDS 2013;27:175-80.
53. Moir S, Ho J, Malaspina A et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med 2008;205:1797-805.
54. Kahan SM, Wherry EJ, Zajac AJ. T cell exhaustion during persistent viral infections. Virology 2015;480C:180-93.
55. Charles ED, Green RM, Marukian S et al. Clonal expansion of immunoglobulin M+CD27 + B cells in HCV-associated mixed cryoglobulinemia. Blood 2008;111:1344-56.
56. Charles ED, Brunetti C, Marukian S et al. Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood 2011;117:5425-37.
57. Terrier B, Joly F, Vazquez T et al. Expansion of functionally anergic CD21-/low marginal zone-like B cell clones in hepatitis C virus infection-related autoimmunity. J Immunol 2011;187:6550-63.
58. Visentini M, Conti V, Cristofoletti C et al. Clonal expansion and functional exhaustion of monoclonal marginal zone B cells in mixed cryoglobulinemia: the yin and yang of HCV-driven lymphoproliferation and autoimmunity. Autoimmun Rev 2013;12:430-5.
59. Carbonari M, Caprini E, Tedesco T et al. Hepatitis C virus drives the unconstrained monoclonal expansion of VH1-69-expressing memory B cells in type II cryoglobulinemia: a model of infection-driven lymphomagenesis. J Immunol 2005;174:6532-9.
60. Knight GB, Gao L, Gragnani L et al. Detection of WA B cells in hepatitis C virus infection: a potential prognostic marker for cryoglobulinemic vasculitis and B cell malignancies. Arthritis Rheum 2010;62:2152-9.
61. Quinn ER, Chan CH, Hadlock KG, Foung SK, Flint M, Levy S. The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood 2001;98:3745-9.
62. Visentini M, Cagliuso M, Conti V, Carbonari M, Casato M, Fiorilli M. The V(H)1-69-expressing marginal zone B cells expanded in HCV-associated mixed cryoglobulinemia display proliferative anergy irrespective of CD21(low) phenotype. Blood 2011;118:3440-1; author reply 2.
63. Weiss GE, Crompton PD, Li S et al. Atypical memory B cells are greatly expanded in individuals living in a malaria-endemic area. J Immunol 2009;183:2176-82.
64. Muellenbeck MF, Ueberheide B, Amulic B et al. Atypical and classical memory B cells produce Plasmodium falciparum neutralizing antibodies. J Exp Med 2013;210:389-99.
65. Illingworth J, Butler NS, Roetynck S et al. Chronic exposure to Plasmodium falciparum is associated with phenotypic evidence of B and T cell exhaustion. J Immunol 2013;190:1038-47.
66. Portugal S, Tipton CM, Sohn H et al. Malaria-associated atypical memory B cells exhibit markedly reduced B cell receptor signaling and effector function. Elife 2015;4: doi: 10.7554/eLife.07218.
67. Ayieko C, Maue AC, Jura WG et al. Changes in B cell populations and merozoite surface protein-1-specific memory B cell responses after prolonged absence of detectable infection. PLoS ONE 2013;8:e67230.
68. Scholzen A, Teirlinck AC, Bijker EM et al. BAFF and BAFF receptor levels correlate with B cell subset activation and redistribution in controlled human malaria infection. J Immunol 2014;192:3719-29.
69. Zinocker S, Schindler CE, Skinner J et al. The V gene repertoires of classical and atypical memory B cells in malaria-susceptible West African children. J Immunol 2015;194:929-39.
70. Warnatz K, Denz A, Drager R et al. Severe deficiency of switched memory B cells (CD27(+)IgM(-)IgD(-)) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease. Blood 2002;99:1544-51.
71. Agarwal S, Cunningham-Rundles C. Autoimmunity in common variable immunodeficiency. Curr Allergy Asthma Rep 2009;9:347-52.
72. Rakhmanov M, Keller B, Gutenberger S et al. Circulating CD21low B cells in common variable immunodeficiency resemble tissue homing, innate-like B cells. Proc Natl Acad Sci USA 2009;106:13451-6.
73. Rakhmanov M, Gutenberger S, Keller B, Schlesier M, Peter HH, Warnatz K. CD21low B cells in common variable immunodeficiency do not show defects in receptor editing, but resemble tissue-like memory B cells. Blood 2010;116:3682-3.
74. Romberg N, Ng YS, Cunningham-Rundles C, Meffre E. Response: common variable immunodeficiency patients with increased CD21(, àí/lo) B cells suffer from altered receptor editing and defective central B-cell tolerance. Blood 2011;118:5977-8.
75. Rubtsov AV, Rubtsova K, Fischer A et al. Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c(+) B-cell population is important for the development of autoimmunity. Blood 2011;118:1305-15.
76. Illges H, Braun M, Peter HH, Melchers I. Reduced expression of the complement receptor type 2 (CR2, CD21) by synovial fluid B and T lymphocytes. Clin Exp Immunol 2000;122:270-6.
77. Yeo L, Lom H, Juarez M et al. Expression of FcRL4 defines a pro-inflammatory, RANKL-producing B cell subset in rheumatoid arthritis. Ann Rheum Dis 2015;74:928-35.
78. Odendahl M, Jacobi A, Hansen A et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000;165:5970-9.
79. Wehr C, Kivioja T, Schmitt C et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood 2008;111:77-85.
80. Saadoun D, Terrier B, Bannock J et al. Expansion of autoreactive unresponsive CD21-/low B cells in Sjogren's syndrome-associated lymphoproliferation. Arthritis Rheum 2013;65:1085-96.